Stock EYEN EYENOVIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Eyenovia, Inc.

Equities

EYEN

US30234E1047

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.7122 USD +13.37% Intraday chart for Eyenovia, Inc. +37.89% -65.76%
Apr. 25 Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension CI
Apr. 08 Eyenovia to Weigh Potential Sale, Other Strategic Alternatives MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
AQ
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension
CI
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives
MT
Eyenovia Explores Wide Range of Strategic Alternatives
CI
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
AQ
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
AQ
Transcript : Eyenovia, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
AQ
North American Morning Briefing : Investors -2-
DJ
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
AQ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
AQ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
CI
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
AQ
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment
MT
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
AQ
US FDA approves Eyenovia's eye drug, Formosa Pharma says
RE
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
AQ
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
CI
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYEN Stock
  4. News Eyenovia, Inc.